Cancer Pharmacology and Pharmacotherapy Review

Study Guide for Oncology Boards and MOC Exams

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Cancer Pharmacology and Pharmacotherapy Review

Study Guide for Oncology Boards and MOC Exams

Authors

Anthony J. Perissinotti, PharmD, BCOP

Bernard L. Marini, PharmD

Editor

Francis P. Worden, MD

Description

Cancer Pharmacology and Pharmacotherapy Reviewis the first book devoted entirely to providing the "must-know" facts on each cancer agent, including their pharmacokinetics, FDA-approved indications,toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review. The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts.

As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeutic, making this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike.

KEY FEATURES

Conveniently organized and arranged by drug class and subtypes for easier recall and classification
Includes proper dosage adjustments to account for liver and kidney dysfunction
Features tables throughout that provide quick reference regarding FDA-approved medications
Simplified diagrams and illustrations facilitate the pharmacokinetic processes

Contents

List of Figures

List of Tables

Preface

I. Traditional Chemotherapy

1. Microtubule Inhibitors

Taxanes and Related Agents

Vinca Alkaloids

2. Alkylating Agents

Nitrogen Mustards

Non-Nitrogen Mustards

Platinums

Antitumor Antibiotics

3. Enzyme Inhibitors—Topoisomerase I Inhibitors

Camptothecans

4. Enzyme Inhibitors—Topoisomerase II Inhibitors

Epipodophyllotoxins

Anthracyclines

5. Antimetabolites

Antifolates

Purine Antagonists

Purine Analogues

Pyrimidine Analogues/Fluoropyrimidines

Pyrimidine Analogues/Deoxycytidine Analogues

II. Next-Generation Antineoplastics

6. Monoclonal Antibodies

7. VEGF Trap

Ziv-Aflibercept (Zaltrap^®)

8. Tyrosine Kinase Inhibitors

Angiogenesis Inhibitors and Multi-Kinase Inhibitors

Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors

B-Cell Receptor (BCR) Pathway Inhibitors

EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors

Miscellaneous Oral Targeted Therapies

9. Antiandrogen Therapies

10. Mammalian Target of Rapamycin (mTOR) Inhibitors

11. Histone Deacetylase (HDAC) Inhibitors

12. Hypomethylating Agents

13. Proteasome Inhibitors

14. Immunomodulatory Agents

15. L-Asparaginase Enzymes

16. Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARα) Translocation Inhibitors

III. Miscellaneous Oncolytics

17. Sipuleucel-T (Provenge^®)

18. Omacetaxine (Synribo^®)

19. Estramustine (Emcyt^®)

Appendix A: Agents Requiring Renal and/or Hepatic Dose Adjustments

Appendix B: Extravasation Risk of Chemotherapeutic Agents

Index

Authors

Francis P. Worden, MD is a Professor of Medicine and Director of the Hematology/Oncology Fellowship Program at the University of Michigan Medical School in Ann Arbor, Michigan.

Anthony J. Perissinotti, PharmD, BCOP, Clinical Pharmacist Specialist in Inpatient Hematology/Oncology and Adjunct Clinical Assistant Professor in Pharmacy, University of Michigan School of Medicine

Bernard L. Marini, PharmD, Clinical Pharmacist, Inpatient Hematology/Oncology, University of Michigan Health System

Product Details